Genzyme touts Renagel data

Genzyme Corporation said its three-year study of 2,100 dialysis patients showed that its Renagel drugs is better than calcium-based phosphate binders at prolonging patients' lives. The drug was particularly effective in those patients treated with Renagel for two years or more, and in those 65 or older.

- read this release for more